<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-16 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-16</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-16</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-3fb1851f9e6b1fe84d142537048ffc2482993957</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/3fb1851f9e6b1fe84d142537048ffc2482993957" target="_blank">Management of acral lentiginous melanoma: current updates and future directions</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> The unique histologic and genetic characteristics of acral lentiginous melanoma make therapy options significantly more challenging, and studies are limited, and data reporting has been inconsistent.</p>
                <p><strong>Paper Abstract:</strong> Acral lentiginous melanoma is a rare subtype of melanoma generally associated with poor outcomes, even when diagnosed at an early stage. The tumor genetic profile remains poorly understood, but it is known to have a suppressed immune environment compared to that of non-acral cutaneous melanomas, which limits therapy options. There is significant attention on the development of novel therapeutic approaches, although studies are limited due to disease rarity. For local disease, wide local excision remains the standard of care. Due to frequent under-staging on preoperative biopsy, wider margins and routine sentinel lymph node biopsy may be considered if morbidity would not be increased. For advanced disease, anti-PD1 monotherapy or combination therapy with anti-PD1 and anti-CTLA4 agents have been used as first-line treatment modalities. Anti-PD1 and anti-CTLA4 combination therapies have been shown to be particularly beneficial for patients with BRAF-mutant acral lentiginous melanoma. Other systemic combination regimens and targeted therapy options may be considered, although large studies with consistent results are lacking. Regional and intralesional therapies have shown promise for cutaneous melanomas, but studies generally have not reported results for specific histologic subtypes, especially for acral melanoma. Overall, the unique histologic and genetic characteristics of acral lentiginous melanoma make therapy options significantly more challenging. Furthermore, studies are limited, and data reporting has been inconsistent. However, more prospective studies are emerging, and alternative therapy pathways specific to acral lentiginous melanoma are being investigated. As further evidence is discovered, reliable treatment guidelines may be developed.</p>
                <p><strong>Cost:</strong> 0.024</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e16.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e16.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801: Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A randomized phase II trial comparing a neoadjuvant + adjuvant pembrolizumab strategy versus adjuvant-only pembrolizumab in patients with resectable stage IIIB–IVC cutaneous melanoma; reported an event‑free survival benefit for the neoadjuvant-containing arm.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Patel et al., N Engl J Med 2023</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2023</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II randomized (neoadjuvant+adjuvant vs adjuvant-only)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant pembrolizumab followed by surgery and adjuvant pembrolizumab vs surgery followed by adjuvant pembrolizumab (adjuvant-only).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable stage IIIB–IVC cutaneous melanoma (ALM represented ~6% of study population).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIB–IVC cutaneous melanoma (as reported in review); resectability per protocol (not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>313</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Neo+adjuvant n=154; adjuvant-only n=159</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant pembrolizumab (same adjuvant regimen in both arms per trial design as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant pembrolizumab (postoperative; duration not specified in review).</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Event-free survival (EFS) reported as the primary comparative endpoint in the review; other endpoints not detailed in review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>Review states an event-free survival benefit for the neoadjuvant+adjuvant group versus adjuvant-only; numerical HRs/CIs/absolute rates not reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Review reports the trial demonstrated an EFS benefit for neoadjuvant exposure, supporting the concept that preoperative systemic exposure can improve outcomes; mechanistic details not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>ALM comprised ~6% of population; no ALM-specific subgroup outcomes reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Review notes limited representation of ALM (6%) and does not provide detailed mechanistic or immune-correlative data; many trial details (doses, timing, HRs) not excerpted in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e16.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>INMC pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>International Neoadjuvant Melanoma Consortium pooled analysis (pathologic response and survival)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A large pooled analysis showing that pathologic complete response (pCR) to neoadjuvant therapy correlates strongly with improved recurrence-free survival and overall survival across multiple neoadjuvant regimens in melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the international neoadjuvant melanoma consortium (INMC).</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the INMC</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>INMC pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Menzies et al., Nat Med 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled analysis of neoadjuvant studies (multicohort translational/pooled clinical analysis).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Pooled cohorts included neoadjuvant ipilimumab+nivolumab (n=104), anti-PD1 monotherapy (n=37), and targeted therapy (n=51); not a single randomized comparison between neo+adj vs adjuvant-only in the pooled analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with operable (typically stage III/IV) cutaneous melanoma enrolled on multiple neoadjuvant studies; histologic subtype analysis not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>ipi+nivo n=104; anti-PD1 n=37; targeted therapy n=51 (as reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Varied by cohort: ipilimumab+nivolumab combination, anti-PD1 monotherapy, or targeted therapy (specific agents/doses depend on original studies; not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Pathologic complete response (pCR) and major pathological response definitions used across studies; review cites pooled analysis definitions but does not standardize them fully in text.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Reported pooled pCR rates by treatment type: targeted therapy 47%, ipilimumab+nivolumab combination 43%, anti-PD1 monotherapy 20% (n/N not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Strong association reported: patients with pCR after neoadjuvant therapy had improved RFS (89% vs 50% at 2 years) and OS (95% vs 83% at 2 years) compared to non-pCR patients (values reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response correlated with RFS and OS; specific trial-level endpoints varied across pooled cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Two-year RFS: 89% for pCR vs 50% for non-pCR (pooled analysis as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td>Two-year OS: 95% for pCR vs 83% for non-pCR (pooled analysis as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>2-year absolute RFS and OS differences as above (RFS 89% vs 50%; OS 95% vs 83%).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The pooled analysis emphasized that achieving pCR predicts favorable survival; immune-correlative details not fully enumerated in the review except percentages by regimen.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and the review argue that pathologic response is a surrogate for improved long-term outcomes and support neoadjuvant strategies that produce high pathologic response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>No histologic-subtype stratification reported in review; subgroup details limited.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Heterogeneity across included neoadjuvant studies (different regimens, definitions, and selection criteria); lack of histologic-subtype reporting (ALM not separately analyzed) noted in review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e16.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Huang single‑dose study</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma (Huang et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Translational study showing that a blood-based 'response signature' measured three weeks after a single neoadjuvant anti‑PD‑1 dose predicts lower recurrence and may serve as an early on‑treatment biomarker of response.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A single dose of neoadjuvant pd-1 blockade predicts clinical outcomes in resectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Huang et al., Nat Med 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Translational mechanistic study (on-treatment biomarker analysis following a single neoadjuvant PD-1 dose).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Patients received one preoperative dose of anti-PD1 (neoadjuvant) and were monitored for a blood 'response signature'; not a randomized comparison to adjuvant-only in the report cited in review.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage III/IV cutaneous melanoma (review does not give ALM-specific details).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage III/IV resectable melanoma (as summarized in review).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Single dose of anti-PD1 (agent/dose not specified in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Single preoperative dose with blood sampled at 3 weeks post-dose (per review description).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Patients who developed the on-treatment 'response signature' had lower disease recurrence than those who showed resistance mechanisms (no HRs provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Recurrence and clinical outcomes associated with blood-based immune signature; specifics not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Identified a peripheral blood 'response signature' at 3 weeks after one neoadjuvant anti‑PD‑1 dose that predicted lower recurrence; suggests rapid systemic immunologic activation after tumor exposure to PD‑1 blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Blood-based 'response signature' measurable 3 weeks after a single neoadjuvant dose correlated with clinical outcomes (detailed analytes not provided in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td>On-treatment blood signature predicted outcomes; review did not enumerate baseline predictors in detail.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors propose that early systemic immune changes induced by tumor‑contained PD‑1 blockade (detectable in blood) are linked to later clinical benefit, supporting neoadjuvant exposure to tumor antigens under checkpoint blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td>The study contrasted patients showing the 'response signature' versus those 'displaying mechanisms of resistance' but details are not provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Review provides only a brief summary; specific cohort size, statistical measures, and full mechanistic data are not presented here.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e16.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo: Optimal combination dosing of neoadjuvant ipilimumab plus nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A multicenter randomized phase II trial comparing three different neoadjuvant dosing schedules of ipilimumab plus nivolumab in macroscopic stage III melanoma, demonstrating high pathological response rates and informing an optimal dosing schedule.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage iii melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Lancet Oncol 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicentre, phase II randomized, controlled (three dosing schedules of ipilimumab+nivolumab in neoadjuvant setting).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Three different neoadjuvant dosing schedules of ipilimumab + nivolumab compared against each other (not vs adjuvant-only).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III melanoma (resectable); histologic subtype not reported separately.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III melanoma (as stated in review).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Combination ipilimumab + nivolumab with varying doses/schedules; group A used ipilimumab 3 mg/kg + nivolumab 1 mg/kg (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Regimens administered once every three weeks; group A received two cycles of ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) q3w (per review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Radiological objective response rates and pathological response rates reported across dosing schedules; survival endpoints not detailed in the review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The trial identified an optimal dosing schedule (group A) producing the highest radiologic and pathological responses, supporting regimen selection for neoadjuvant combination therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Implicit mechanistic claim: certain neoadjuvant dosing schedules of CTLA‑4 + PD‑1 blockade yield higher intratumoral and clinical responses, suggesting regimen/timing affects tumor–immune priming.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Review notes lack of histologic-subtype reporting and does not detail safety/tolerability in this summary; sample sizes per schedule not specified in review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e16.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO (OpACIN-neo extension)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PRADO trial: Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An extension cohort of OpACIN-neo where neoadjuvant ipilimumab+nivolumab pathologic response was used to personalize subsequent surgery and adjuvant therapy, showing high pathologic response rates and that patients with major pathologic response could omit further lymph node dissection and adjuvant therapy with favorable 2‑year outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO (OpACIN-neo extension cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Reijers et al., Nat Med 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Single-arm extension cohort (personalized surgical/adjuvant management based on neoadjuvant path response) of OpACIN-neo.</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>All patients received neoadjuvant ipilimumab + nivolumab; subsequent surgery and adjuvant therapy were tailored based on index-node pathologic response (MPR, partial response, non-response).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>99 patients with stage IIIB–D nodal cutaneous melanoma (high-risk stage III) (histologic subtype not reported separately).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage IIIB–D nodal cutaneous melanoma (as stated in review).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab (dosing per OpACIN-neo schedules; specific regimen in PRADO not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Personalized: patients with major pathologic response omitted further adjuvant therapy; partial responders had therapeutic lymph node dissection; non-responders had dissection + adjuvant systemic therapy ± radiotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Major pathologic response (MPR) defined as ≤10% viable tumor in the index lymph node (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Major pathologic response rate 61% (definition ≤10% viable tumor); overall pathologic response rate 72% (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Patients with MPR had favorable 2-year relapse-free survival and distant metastasis-free survival such that omission of therapeutic lymph node dissection and adjuvant therapy was considered safe in that group (numerical HRs/CIs not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates, 2‑year RFS and DMFS used to make management recommendations; exact survival numbers not provided in review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Two-year RFS and DMFS used to support omission of further therapy in MPR patients; precise percentages not given in review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td>Two-year DMFS used in decision-making; exact values not reported in review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>PRADO authors and the review argue that pathologic response after neoadjuvant combination therapy can identify patients who may safely avoid more extensive surgery and adjuvant therapy — implying that tumor-directed preoperative immunity is predictive and possibly causally linked to long-term control.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm design for personalized management; lack of histologic-subtype-specific data (ALM not separately reported) and absence of randomized comparison to standard approaches in this cohort, per review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e16.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amaria relatlimab+nivo neoadjuvant</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma (Amaria et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A neoadjuvant study testing the LAG‑3 inhibitor relatlimab combined with nivolumab in resectable stage III or oligometastatic stage IV melanoma, reporting high pathologic complete and overall pathologic response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Amaria et al., Nature 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Neoadjuvant translational clinical study (combination LAG‑3 + PD‑1 blockade) in resectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant relatlimab + nivolumab administered prior to surgery; not compared head-to-head with adjuvant-only in the cited review text.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable stage III or oligometastatic stage IV cutaneous melanoma (histologic subtypes not reported separately).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage III or oligometastatic stage IV (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Relatlimab (LAG‑3 inhibitor) combined with nivolumab (PD‑1 inhibitor); exact dosing not specified in review.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pathologic complete response (pCR) rate 57% (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Overall pathologic response rate 70% (definitions per study; review does not list MPR threshold).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates reported; survival endpoints not detailed in the review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Study suggests combining LAG‑3 and PD‑1 blockade preoperatively yields high pathological responses, supporting the concept that neoadjuvant dual checkpoint blockade can elicit potent antitumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Review notes lack of histologic-subtype reporting (ALM not separately analyzed) and does not provide detailed immune-correlative readouts in the summary.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Management of acral lentiginous melanoma: current updates and future directions', 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the international neoadjuvant melanoma consortium (INMC). <em>(Rating: 2)</em></li>
                <li>A single dose of neoadjuvant pd-1 blockade predicts clinical outcomes in resectable melanoma. <em>(Rating: 2)</em></li>
                <li>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage iii melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. <em>(Rating: 2)</em></li>
                <li>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage iii melanoma: The PRADO trial. <em>(Rating: 2)</em></li>
                <li>Neoadjuvant relatlimab and nivolumab in resectable melanoma. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>